Cost-effectiveness of voluntary HIV screening in Russia

International Journal of STD and AIDS

Volumn 20, Issue 1, 2009, Pages 46-51

  Tole, Swati P ^a,g   Sanders, G D ^b   Bayoumi, A M ^c,d   Galvin, C M ^a   Vinichenko, T N ^a   Brandeau, M L ^e   Owens, D K ^a,f  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Stanford University   (United States)

^f VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^g STANFORD UNIVERSITY   (United States)

Author keywords

AIDS; Cost effectiveness; HIV; Prevention; Russia; Screening

Indexed keywords

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUNSELING; ECONOMICS; EPIDEMIC; HEALTH CARE COST; HEALTH EDUCATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; LIFESPAN; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK REDUCTION; RUSSIAN FEDERATION; SCREENING; SENSITIVITY ANALYSIS; SEXUAL TRANSMISSION; SURVIVAL; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AIDS SERODIAGNOSIS; COST-BENEFIT ANALYSIS; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; PREVALENCE; QUALITY OF LIFE; RUSSIA; VOLUNTARY PROGRAMS; YOUNG ADULT;

EID: 58249117963     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2008.008128     Document Type: Article

References (60)

1. AIDS Foundation East-West (AFEW). Officially Registered Cases in the Russian Federation, 1 January 1987-30 September 2007. Moscow: AFEW, 2007
2. Csete J. Lessons not learned: human rights abuses and HIV/AIDS in the Russian Federation. Human Rights Watch 2004;16:1-64
3. United Nations Development Programme (UNDP). HIV/AIDS in Eastern Europe and the Commonwealth of Independent States: Reversing the Epidemic, Facts and Policy Options. Bratislava: UNDP, 2004
4. EuroHIV. HIV/AIDS Surveillance in Europe: End-year Report 2005. Report No. 72. Saint-Maurice: Institut de Veille Sanitaire, 2006
5. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2006 AIDS Epidemic Update: Eastern Europe and Central Asia. Geneva: UNAIDS, 2006
6. World Health Organization (WHO). Summary of Country Profile for HIV/AIDS Treatment Scale-up: Russian Federation, December 2005. Geneva: WHO, 2006
7. National Intelligence Council. The Next Wave of HIV/AIDS: Nigeria, Ethiopia, Russia, India, and China. Washington, DC: National Intelligence Council, 2002
8. Feshbach M, Galvin CM. HIV/AIDS in Russia - An Analysis of Statistics. Washington, DC: Woodrow Wilson International Center for Scholars, 2005
9. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005;352:570-85
10. Chou R, Huffman LH, Fu R, Smits AK, Korthuis PT. Screening for HIV: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2005;143:55-73
11. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921-9
12. The National Institute of Mental Health (NIMH) Multisite HIV Prevention Trial Group. The NIMH Multisite HIV Prevention Trial: reducing HIV sexual risk behavior. Science 1998;280:1889-94
13. DiClemente RJ, Wingood GM. A randomized controlled trial of an HIV sexual risk-reduction intervention for young African-American women. J Am Med Assoc 1995;274:1271-6
14. Kamb ML, Fishbein M, Douglas JM Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. J Am Med Assoc 1998;280:1161-7
15. Cartwright K. Problems with Russia's Compulsory Screening for HIV/AIDS. Washington, DC: Urban Institute and World Bank, 2001
16. Twigg JL, Skolnik R. Evaluation of the World Bank's Assistance in Responding to the AIDS Epidemic: Russia Case Study. Washington, DC: World Bank, 2005
17. Moskovsky Komsomolets, Volume 35, Sect. 4, 1999
18. Irwin K, Heimer R, Smoyer A. Drug Policy and HIV Prevention in Russia: The Case of HIV/AIDS Prevention. New Haven: Center for Interdisciplinary Research on AIDS, Yale University, 2004
19. Owens DK, Sundaram V, Lazzeroni LC, et al. Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs Health Care Systems: implications for screening programs for HIV. Am J Public Health 2007;97:2173-8
20. Paltiel AD, Walensky RP, Schackman BR, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med 2006;145:797-806
21. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med 2005;352:586-95
22. Walker D. Cost and cost-effectiveness of HIV/AIDS prevention strategies in developing countries: is there an evidence base? Health Policy Plan 2003;18:4-17
23. World Health Organization (WHO). The World Health Report 2002 - Reducing Risks, Promoting Healthy Life. Geneva: WHO, 2002
24. World Health Organization (WHO). Progress on Global Access to HIV Antiretroviral Therapy: A Report on "3 by 5" and Beyond. Geneva: WHO, 2006
25. Federal State Statistics Service. Population by Age Groups. Moscow: Goskomstat, 2004
26. Kozlov AP, Shaboltas AV, Toussova OV, et al. HIV incidence and factors associated with HIV acquisition among injection drug users in St Petersburg, Russia. AIDS 2006;20:901-6
27. Hogan D, Salomon J. Prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome in resource-limited settings. Bull World Health Organ 2005;83:135-43
28. Kalichman SC, Cain D, Weinhardt L, et al. Experimental components analysis of brief theory-based HIV/AIDS risk-reduction counseling for sexually transmitted infection patients. Health Psychol 2005;24:198-208
29. Valdiserri RO, Ogden LL, McCray E. Accomplishments in HIV prevention science: implications for stemming the epidemic. Nat Med 2003;9:881-6
30. Wiktor SZ, Abouya L, Angoran H, et al. Effect of an HIV counseling and testing program on AIDS-related knowledge and practices in tuberculosis clinics in Abidjan, Cote d'Ivoire. Int J Tuberc Lung Dis 2004;8:445-50
31. Finnerty E. Opiate substitution treatment in the former Soviet Union. Lancet 2006;368:1066
32. Zandonella C. International AIDS Vaccine Initiative (IAVI) Report. New York: IAVI, 2006
33. Bobrik A. Expected Price of the Cheapest ARV Regimens. Moscow: Open Health Institute, 2005
34. Boykewich S. Supply of anti-HIV drugs falls short. Moscow Times, 16 August 2005
35. Bayoumi AM, Redelmeier DA. Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. AIDS 1998;12:1503-12
36. Gable CB, Tierce JC, Simison D, Ward D, Motte K. Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:413-20
37. Honiden S, Sundaram V, Nease RF, et al. The effect of diagnosis with HIV infection on health-related quality of Life. Qual Life Res 2006;15:69-82
38. Keiser P, Kvanli MB, Turner D, et al. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration Hospital. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:28-33
39. Revicki DA, Wu AW, Murray MI. Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Med Care 1995;33:AS173-82
40. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making 2002;22:475-81
41. Tsevat J, Sherman SN, McElwee JA, et al. The will to live among HIV-infected patients. Ann Intern Med 1999;131:194-8
42. Tsevat J, Solzan JG, Kuntz KM, et al. Health values of patients infected with human immunodeficiency virus: relationship to mental health and physical functioning. Med Care 1996;34:44-57
43. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 2000;90:1100-11
44. World Health Organization (WHO). Life Tables for WHO Member States: Russian Federation - 2004. Geneva: WHO, 2004
45. Rakhmanova A. VICH Infektsiya v Rossii [HIV Infection in Russia]. Epidemic situation and priorities in halting the spread of HIV infection in the Russian Federation. AIDS J: AIDS Sex and Health, Available from [http://www.aidsjournal.ru/journal/54-17.html] (Accessed 24 August 2005)
46. Amirkhanian YA, Kelly JA, McAuliffe T. Psychosocial needs, mental health, and HIV transmission risk behavior among people living with HIV/AIDS in St. Petersburg, Russia. AIDS 2003;17:2367-74
47. Erickson B, Wasserheit JN, Rompalo AM, Brathwaite W, Glasser D, Hook WE. Routine voluntary HIV screening in STD clinic clients: characterization of infected clients. Sex Transm Dis 1990;17:194-9
48. Hightow L, Miller W, Leone P, Wohl D, Smurzynski M, Kaplan A. Failure to return for HIV posttest counseling in an STD clinic population. AIDS Educ Prev 2003;15:282-90
49. Holman S, Sorin M, Crossette J, LaChance-McCullough M. A state program for postpartum HIV counseling and testing. Public Health Rep 1994;109:521-9
50. Irwin K, Olivo N, Schable C, Weber J, Janssen R, Ernst J. Performance characteristics of a rapid HIV antibody assay in a hospital with a high prevalence of HIV infection. CDC-Bronx-Lebanon HIV Serosurvey Team. Ann Intern Med 1996;125:471-5
51. Kassler W, Dillon B, Haley C, Jones W, Goldman A. On-site, rapid HIV testing with same-day results and counseling. AIDS 1997;11:1045-51
52. Kelen G, Hexter D, Hansen K, et al. Feasibility of an emergency department-based, risk-targeted voluntary HIV screening program. Ann Emerg Med 1996;27:687-92
53. Sullivan P, Lansky A, Drake A. Failure to return for HIV test results among persons at high risk for HIV infection: results from a multistate interview project. J Acquir Immune Defic Syndr 2004;35:511-8
54. Mylonakis E, Paliou M, Lally M, Flanigan TP, Rich JD. Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am J Med 2000;109:568-76
55. Owens DK, Nease RF Jr, Harris RA. Cost-effectiveness of HIV screening in acute care settings. Arch Intern Med 1996;156:394-404
56. Schwartz JS, Kinosian BP, Pierskalla WP, Lee H. Strategies for screening blood for human immunodeficiency virus antibody: use of a decision support system. J Am Med Assoc 1990;264:1704-10
57. Centers for Disease Control. Update: serologic testing for antibody to human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1988;36:833-40, 45
58. MacDonald KL, Jackson JB, Bowman RJ, et al. Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors: public health and clinical implications. Ann Intern Med 1989;110:617-21
59. World Health Organization (WHO). Per Capita Total Expenditure on Health at Average Exchange Rate (US$). Geneva: WHO, 2001
60. Adeyi O, Baris E, Chakraborty S, Novotny T, Pavis R. Averting AIDS Crises in Eastern Europe and Central Asia. Washington, DC: World Bank, 2003